Cardiovascular effects of cancer drugs: Review

Basit Öğe Kaydı
dc.authorscopusid8708323300
dc.authorscopusid23489239400
dc.authorscopusid7801566797
dc.contributor.authorAktürk E.
dc.contributor.authorKurto?lu E.
dc.contributor.authorErmiş N.
dc.date.accessioned2024-08-04T20:02:14Z
dc.date.available2024-08-04T20:02:14Z
dc.date.issued2014
dc.departmentİnönü Üniversitesien_US
dc.description.abstractWidening the array of active antineoplastic agents has resulted in a prolongation of lifespan of cancer patients, but also increased the possibility of manifestation of adverse effects of anticancer treatment. Cardiovascular toxicity is a potential short- or long-term complication of anticancer therapy. The mechanisms of particular cardiovascular toxicities in cancer patients may differ from those of general population and the presence of cancer may limit the therapeutic options. Therefore, general treatment guidelines in cardiovascular disorders may not be appropriate in cancer patients. Additionally, cardiovascular toxicities reported in clinical trials do not always reflect those of "real world" patients. More research is needed to assess and manage the cardiovascular safety of patients treated with anticancer agents, beginning with a dynamic partnership between oncologists and cardiologists and the development of a new generation of "cardiooncologic" investigators. Cardiac toxicity associated with cancer therapies can range from asymptomatic subclinical abnormalities, including electrocardiographic changes and temporary left ventricular ejection fraction decline, to life-threatening events such as heart failure or acute coronary syndromes. The aim of this review is to summarize potential cardiovascular toxicities for a range of cancer chemotherapeutics. Given the rate of new drug development designed to fulfill unmet oncologic needs, efforts are needed to promote strategies for cardiac risk detection and management and to avoid unintended consequences potentially impeding development of, regulatory approval for, manage the cardiovascular safety of patients treated with anticancer agents, as well as a well-organized collaboration between oncologists and cardiologists. Copyright © 2014 by Türkiye Klinikleri.en_US
dc.identifier.endpage25en_US
dc.identifier.issn1306-7656
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-84902360957en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage16en_US
dc.identifier.urihttps://hdl.handle.net/11616/91531
dc.identifier.volume26en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherTurkiye Kliniklerien_US
dc.relation.ispartofTurkiye Klinikleri Cardiovascular Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAngiogenesis inhibitorsen_US
dc.subjectAntineoplastic agentsen_US
dc.subjectDrug toxicityen_US
dc.subjectRisk factorsen_US
dc.titleCardiovascular effects of cancer drugs: Reviewen_US
dc.title.alternativeKanser i?laçlari{dotless}ni{dotless}n kardiyovasküler etkilerien_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu